絞り込み

16640

広告

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.

著者 Dimopoulos MA , Goldschmidt H , Niesvizky R , Joshua D , Chng WJ , Oriol A , Orlowski RZ , Ludwig H , Facon T , Hajek R , Weisel K , Hungria V , Minuk L , Feng S , Zahlten-Kumeli A , Kimball AS , Moreau P
Lancet Oncol.2017 Aug 23 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (153view , 1users)

Full Text Sources

Medical

Miscellaneous

The phase 3 ENDEAVOR trial was a head-to-head comparison of two proteasome inhibitors in patients with relapsed or refractory multiple myeloma. Progression-free survival was previously reported to be significantly longer with carfilzomib administered in combination with dexamethasone than with bortezomib and dexamethasone in an interim analysis. The aim of this second interim analysis was to compare overall survival between the two treatment groups.
PMID: 28843768 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード